Skip to main content

The Clinical Challenge
How Important Is the First Year of PAH Therapy?

Join the peer-to-peer pulmonary arterial hypertension (PAH) roundtable to hear the data examining clinical decisions that can lead to improved patient outcomes

PAH Experts Examine First-Year Treatment Goals


The Clinical Challenge: How Important Is the First Year of PAH Therapy?

Join PAH experts for a dynamic roundtable discussion examining why achieving low risk in the first year remains the therapeutic goal for most patients, as well as evaluating whether the partial success of intermediate-low risk is satisfactory

Through evidence-based discussion and real-world clinical experience, faculty will translate guideline-informed goals into real-world PAH care decisions

This is a disease education program sponsored by the PAH Initiative. No product information will be discussed.

Expert panel

Yuri Matusov

Yuri Matusov
MD, FACP, ATSF

Pulmonologist

Anjali Vaidya

Anjali Vaidya
MD, FACC, FASE, FACP

Cardiologist

Sandeep Sahay

Sandeep Sahay
MD, MSc, FCCP, ATSF

Pulmonologist

Moderator

Franck Rahaghi

Franck Rahaghi
MD, MHS, FCCP

Pulmonologist

Topics covered

Increase icon

Clinical data linking early risk reduction with improved long-term outcomes

Echo machine icon

How frequent right heart evaluations can guide timely treatment decisions

Heartbeat icon

How outcomes may differ when treatment goals are not achieved in the first year

This a non-CME credit event and does not qualify for CME, CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2026 conference sessions. This event is not endorsed by CHEST and does not reflect the views and opinions of CHEST.

Learn more about the first year of PAH Therapy

Why Get to Low Risk Quickly?